| Contracts are critical in life sciences. At each step in the product life cycle, pharma, biotech and medtech companies need to engage with third parties to develop, manufacture and sell their drugs, diagnostics and devices. With lives at stake and multiple players pursuing opportunities, companies that close deals quickly have a competitive edge. Yet, each contract exposes a company to an array of major third-party risks, creating a need for systems that support both speed and quality.
| |
